Hematopoietic cell transplantation (HCT) following nonmyeloablative conditioning (NMSCT) may be associated with a reduced risk of infection compared to standard allogeneic HCT. We retrospectively analyzed incidence and risk factors of infection in 62 patients undergoing NMSCT with low-dose TBI þ /À fludarabine and postgrafting CsA and MMF. The proportion of patients with any infection was 77%, but the majority of infectious events occurred beyond day 30. Donor other than sibling, older age, early disease and male gender were significant risk factors. The incidence of bacteremia was 55% at 1 year and the number of bacteremic episodes was 0.9 per patient (0.08 before day 30). The risk of bacteremia increased with older age and the use of a donor other than an HLA-identical sibling, but not with neutropenia. The incidence of infections other than bacteremia correlated with the use of corticosteroids. The risk of CMV infection increased with high-risk CMV serology, and risk of CMV disease with high-risk CMV serology, older age, first transplantation and a diagnosis of lymphoma. In conclusion, after NMSCT, infections are not frequent in the first 30 days post transplant but careful long-term monitoring is necessary thereafter.
Introduction
Allogeneic hematopoietic stem cell transplantation (allohematopoietic cell transplantation (HCT)) with a myeloablative conditioning remains the only curative treatment for several hematological malignancies. 1 However, because of its toxicity, this approach is restricted to younger and fitter patients. This observation led several groups to set up transplant protocols with a nonmyeloablative conditioning (NMSCT for 'nonmyeloablative stem cell transplantation') in which elimination of malignant cells is shifted from the preparative regimen to the GVL effect. 2, 3 The Seattle team proposed an original approach to NMSCT with a conditioning regimen based on single dose (2 Gy) TBI þ /À fludarabine (90 mg/m 2 ), followed by post-transplant immunosuppression with cyclosporine A (CsA) and mycophenolate mofetil (MMF) that permitted undertaking the transplant in an ambulatory care setting. [4] [5] [6] The authors observed a low transplant-related mortality (even in older patients), which was most often attributed to graft-versushost disease (GVHD) and/or infections. 5, 6 Thus, one major objective to improving outcome following NMSCT is to achieve rapid immune reconstitution (to permit the occurrence of the GVL effect 7 and avoid opportunistic infections), without severe GVHD.
Infections represent up to 63% of causes of death in standard allogeneic transplant recipients at the time of autopsy. 8 Theoretically, NMSCT could be associated with a reduced risk of infection because they cause less disruption to the gastrointestinal mucosa [9] [10] [11] and less severe neutropenia. 9, 12, 13 In addition, the prolonged presence of host immunity could provide some protection against infectious events.
14 However, it is not yet clear whether NMSCT will indeed result in a reduced risk of infection compared to standard myeloablative allogeneic transplantation. Available data have sometimes indicated a reduced incidence of infection after NMSCT 9,10 but other studies have observed similar rates of infection after the two forms of allogeneic transplantation. 11, 12, [15] [16] [17] [18] We therefore conducted a retrospective study to describe the incidence and types of infection in 62 recipients of a NMSCT in our institution.
Patients and methods

Patients
Patient characteristics are described in Table 1 . The study population included 62 consecutive patients, 16 females and 46 males, aged 54711 years (M7s.d.), who had undergone NMSCT between March 2000 and May 2003. NMSCT were performed in patients deemed unfit for HCT with myeloablative conditioning because of age (455 years for sibling or 450 years for UD transplants), comorbidity (poor organ function or active infection) or relapse after a conventional transplant. Among them, 55 had hematological malignancies and seven had renal cell carcinoma, one-third with early disease (untreated or 1st partial (PR) or complete (CR) remission) and two-thirds at more advanced stages. The donor was an HLA-identical sibling in about 50% of the cases and an alternative donor in the other 50%. All patients on study were followed up for a minimum of 6 months or until death. Patients and donors gave written informed consent for the transplant procedure, as well as to the collection and analysis of their clinical data, and this was approved by the Ethics Committee of the University of Lie`ge.
Clinical management
In accordance with the regimen developed by the Seattle team, 19 patients received low-dose TBI (2 Gy) either alone (n ¼ 19) or with fludarabine (90 mg/m 2 ) (n ¼ 33). Cyclophosphamide (3 g/m 2 ) was substituted for TBI when previous irradiation precluded TBI (n ¼ 10). PBSC were mobilized with G-CSF 10 mg/kg/day. Graft manipulations consisted of CD8 depletion (n ¼ 28) or CD34 selection (n ¼ 7). An average dose of 5.772.9 Â 10 6 CD34 þ cells/kg was infused. Post-transplant immunosuppression was with Cyclosporine A (CsA, from day À1 to day 180 or longer in case of alternative donor or chronic GVHD), and mycophenolate mofetil (MMF, 15 mg/kg b.i.d. from day À1 to day 28 or day 42 in case of alternative donor, as previously described. 14, 20 The diagnosis and grading of acute GVHD was established as previously reported. 21 First-line treatment of GVHD consisted of corticosteroids (2 mg/kg). G-CSF (5 mg/kg/day) was administered only when the granulocyte count was below 1.0 Â 10 9 /l. Disease evaluation was routinely carried out on days 40, 100, 180 and 365. All patients had a central venous catheter device. DLI were given either prophylactically after CD34 selection or in the event of poor chimerism or relapse.
Infection prophylaxis and treatment
Patients also received acyclovir (400 mg t.i.d. orally), oral antifungal prophylaxis with itraconazole solution (200 mg b.i.d.) and aerosolized pentamidine, but no antibacterial prophylaxis, until the end of immunosuppressive therapy. In the event of fever above 38.31C once or above 381C on three consecutive measurements, empirical antibiotherapy was started with a combination of cefepime þ amikacin. Before the initiation of antibiotherapy, blood cultures were drawn through each lumen of the central catheter and a peripheral vein. Additional blood cultures were obtained when clinically indicated. Patients were screened weekly for CMV by antigenemia and PCR in blood. Pre-emptive therapy with ganciclovir was initiated after a positive antigenemia or PCR and discontinued after day 100 and at least three consecutive negative results.
Definitions
According to the definitions of the Infectious Diseases Working Party of the EBMT, bacteremia or fungemia were defined by the isolation of bacteria or fungi from any blood culture in the context of fever or other clinical signs consistent with infection. 22 For coagulase-negative staphylococci, at least two blood cultures with the same antimicrobial susceptibilities were required to be positive. Varicella-zoster virus (VZV) infections were defined as typical cutaneous vesicular lesions or atypical lesions associated with the detection of VZV by culture or IF. Any positive result on CMV screening was considered as CMV infection whereas CMV disease was defined by the evidence of CMV infection at one body site (PCR or histopathologic finding) in association with clinical signs or symptoms. Invasive fungal infections were defined according to the EORTC criteria. 23 Fever of unknown origin was defined as fever alone without any clinical sign or bacteriological documentation.
Statistical analysis
Patient characteristics (Table 1 ) and proportions of patients with a given number of infections (Table 2) were analyzed by appropriate contingency tables. Times to infectious events were studied by Kaplan-Meier analyses. Univariate and multivariate Cox regression models were used to analyze the influence of selected variables on the risk of infection. Times to events were the outcomes, with censoring at time of subsequent transplant, death or last follow-up. Variables were selected with a forward stepwise procedure (criterion Po0.05) and P-values were calculated with the likelihood ratio test. Statistical analyses were carried out using Microsoft Excel (Microsoft Corp., Redmond, WA, USA), GraphPad Prism (GraphPad Software, San Diego, CA, USA) and SAS (SAS Institute, Cary, NC, USA) softwares.
Results
Types of infection
No patients experienced toxic mucositis or significant gastrointestinal toxicity. The mean neutrophil nadir was 580/ml (range 0-3000). In 35 patients, the neutrophil count did not decrease below 500/ml. Patients received G-CSF for a mean of 5.5 (0-17) days. The median time to 1000 PMN/ ml was 8.5 days. There were 25 deaths (40%). Of the deaths, 60% were due to relapse/progression of the underlying disease. Infection was the primary cause of death in 10% of patients but infections contributed to death in 24% of them. The proportion of patients experiencing any infection during the course of their follow-up was 77% (Table 2 ) but the majority of these first infections occurred well beyond day 30 post transplantation ( Figure 1a) .
The actuarial incidence of bacteremia at 1 year was 55% (Figure 1b) . Overall, there were 0.9 episode of bacteremia/ patient (Table 3) . However, these bacteremias were seldom Only infections before disease progression were considered. Infections in nonmyeloablative HCT P Frère et al (0.08 per patient at risk) observed in the first 30 days post transplant. The largest number of bacteremias was due to coagulase-negative staphylococci (41%). Gram-negative bacteria accounted for 25% of events. Other agents causing bacteremias included streptococci (9%), miscellaneous other bacteria (21%) and fungi (4%). The actuarial incidence at 1 year of infections other than bacteremia was 72%, but again these infections were significantly delayed (Figure 1c) . The major types of such infections were pneumonias and upper respiratory tract (URT) infections (Table 3) .
Infectious agents
Before day 30, the main agents responsible for infections were bacteria (N ¼ 18 (82%)) and that dominance persisted throughout the observation period (Table 3) . Again there was a low incidence of bacterial infections (n ¼ 17, 0.27/ patient at risk) in the first 30 days following transplantation. Considering all infectious episodes, Gram-positive bacteria were the agents most frequently responsible for infection: coagulase-negative staphylococci were involved in 24/132 events and streptococci in 10/132 events. Gramnegative bacteria were involved in 28/132 cases and miscellaneous other bacteria in 15/132 cases.
Fungal infections represented an incidence of 0.03 event/ patient at risk before day 30, but their incidence tended to increase thereafter (0.10/patient at risk between days 100 and 365) ( Table 3) . Candidas were identified in 5% of infectious episodes, while aspergillus was documented in 7% of all infections. However, there was a further 3% incidence of possible fungal infections.
The actuarial incidence of VZV infection was 10% at 1 year. The actuarial incidences of CMV infection and disease were 52 and 18%, respectively (Figure 2 ). No case of CMV reactivation or disease occurred among the lowrisk patients (donor and recipient serologically negative). After excluding low-risk patients, rates of CMV infection and disease were 68 and 23%, respectively, that is, 36 and 9% in the intermediate-risk group (donor seropositive and recipient seronegative), and 80 and 26%, in the high-risk category (recipient seropositive) ( Table 4) .
Risk factors for infection
We then examined, by univariate and multivariate analysis, risk factors for infection, separately analyzing all infections, bacteremias, infections other than bacteremia, CMV infection and CMV disease, interstitial pneumonia and VZV infection. These factors included data concerning the donor (relationship to patient, age, sex, ABO compatibility, CMV status), patient (age, sex, diagnosis, pretransplant disease status, CMV status), transplant procedure (conditioning regimen, consecutive number of the transplant, graft manipulation, use of DLI) and complications (neutropenia, aGVHD, cGVHD, use of corticosteroids).
When looking at the overall risk of infection, we identified by univariate analysis donor other than HLAidentical sibling (P ¼ 0.0077) and absence of DLI as significant risk factors (P ¼ 0.0132). On multivariate analysis, only having a donor other than a HLA-identical sibling (P ¼ 0.0010) was a significant risk factor.
For bacteremia, by univariate analysis only donor source reached statistical significance, with a 1-year 43% incidence Only infections before disease progression were considered
Infections in nonmyeloablative HCT P Frère et al of bacteremia with a sibling donor and 66% with an alternative donor (P ¼ 0.0061). This result was confirmed on multivariate analysis (P ¼ 0.0015), where the risk of bacteremia also increased with age of the recipient (P ¼ 0.0064).
For infections other than bacteremia, only administration of DLI was associated with an increased risk (P ¼ 0.00440) by univariate analysis, whereas by multivariate analysis only the use of corticosteroids increased the risk (P ¼ 0.0066).
By univariate analysis, only high-risk pretransplant CMV status (R þ /DÀ, R þ /D þ ) (Po0.0001) influenced the risk of CMV infection, which nevertheless tended to be higher in older patients (P ¼ 0.0721) and patients with a donor other than an HLA-identical sibling (P ¼ 0.0679). By multivariate analysis, the risk of CMV infection increased only with high-risk CMV status (Po0.0001) and, among these patients, no additional factor was identified.
Similarly, on univariate analysis, the risk of CMV disease increased in patients with high-risk pretransplant CMV status (P ¼ 0.0054). Among these patients, by multivariate analysis, the risk of CMV disease increased with the age of the patient (P ¼ 0.0137), a first transplant (P ¼ 0.0057) and a diagnosis of lymphoma (P ¼ 0.0010).
Discussion
NMSCT are usually reserved for patients unable to undergo myeloablative conditioning because of older age, poor clinical condition or previous transplantation with a high-dose regimen. It is therefore impossible to select, for the purpose of comparison, an appropriately matched group of patients undergoing transplantation after standard, myeloablative conditioning. Compared to myeloablative regimens, NMSCT is associated with less myelotoxicity and produces fewer extrahematological toxicities, in particular less damage to the mucosal barriers of the gastrointestinal tract. [9] [10] [11] 24 However, the relative intensity of these treatments ranges from the reducedintensity conditioning (RIC) regimens that still induce severe neutropenia and are carried out in protected in-patient units, 10, 15, 25, 26 to the truly nonmyeloablative regimen developed by the Seattle team that causes little neutropenia, can be performed in outpatients and cause much less morbidity. 9, 12, 13, 24 Using the Seattle regimen, we indeed encountered virtually no toxic mucositis and no gastrointestinal toxicity. In addition, we have previously shown that this regimen was associated with little myelosuppression 20 and with prolonged persistence of host immune cells.
14 However, it was not clear whether these factors have the potential of providing some protection against infections.
In our population of 62 NMSCT recipients, the proportion of patients developing any infection during follow-up was 77%. This overall proportion is quite similar to the one found after standard allogeneic transplantation, 20, 27 but the majority of these first infections occurred well beyond day 30 post transplantation ( Figure 1a) . Although earlier papers in small numbers of patients were widely discrepant in that respect, 11, 18 this reduced rate of early infection 10 and the delayed time to first infection 9,10 in NMSCT recipients have also been described by others. Therefore, the absence of mucosal damage and of neutropenia in many NMSCT patients possibly confered some protection against early infections in our patients. This is consistent with a previous study showing that neutropenia at initiation of a RIC is already a risk factor for subsequent infection in the early post transplant period. 15 However, in our hands, among NMSCT recipients, those with early neutropenia did not have a higher rate of early infection.
Bacteria were evidently the leading agents causing infection. This was particularly true in the early post transplant phase, but also remained so thereafter, albeit to a lesser extent. Among them, Gram-positive bacteria were the agents most frequently responsible for infection, in agreement with data from standard allogeneic transplantation [27] [28] [29] [30] and probably related to the fact that all patients carried a central venous catheter device. Similarly, the pattern of fungal infections was consistent with previous studies 9, 10 that reported incidences of proven or probable fungal infection in NMSCT recipients 12, 16, 17 comparable to those observed in standard transplants after a myeloablative conditioning.
31,32 Some 9,12,16 but not all 17 previous studies have shown that advanced disease, age above 40 years, GVHD, corticosteroid use, CMV infection or relapse were predictive of fungal infections in NMSCT patients, but the number of patients with such infections in our series was too small to analyze these factors.
After excluding seronegative patients with a seronegative donor, the actuarial incidences of CMV infection and CMV disease were 68 and 23%, respectively. In some previous studies, CMV infection and disease have been delayed after NMSCT. 13, 33 It is hypothesized that residual host T lymphocytes may contribute to resistance to CMV disease and that, as the level of these cells declines over time, the risk of infection increases. 34 However, similar to some other studies, 26 we did not observe any such delay in NMSCT recipients. On the other hand, the incidence of CMV infection and disease was clearly dependent on recipient and donor serostatus. 13, 17, 26, 33 In addition, older age and an alternative donor, but not the use of corticosteroids, 17 acute GVHD, 26 graft manipulation 26 or use of fludarabine for conditioning, 35 tended to be risk factors for CMV infection. However, it cannot be excluded that the fact that CMV disease was more frequent after a first transplant may, in fact, be related in part to the use of fludarabine, as the vast majority of patients not receiving this drug were second transplants. Although this was not found for CMV infection, older age was indeed associated with CMV disease on multivariate analysis. It has also been suggested that the use of ATG or Campath-1H in the conditioning regimen 25 or the use of MMF post transplant 36 could enhance the risk of CMV infection and disease, but this is not evaluable in our series. Chronic GVHD has been recognized as a significant risk factor after conventional allogeneic transplantation, 37 but not after NMSCT.
Bacteremias occur in about 20-60% of the cases after allogeneic HCT. 28 In our study, the incidence of bacteremia at 1 year was 55%. In addition, occurrence of bacteremia was again delayed beyond the first 30 days. Contrary to the findings of others using a similar conditioning regimen, 9 neutropenia was not a risk factor for bacteremia. In agreement with others, 17 the agents responsible for bacteremias were mainly coagulase-negative staphylococci, and in general, Gram-positive bacteria were the agents most often responsible for infection. This result is totally in agreement with the literature. 17 A number of risk factors were consistently identified on univariate and multivariate analysis. Age above 60 years and use of an alternative donor were often associated with an increased risk of overall infection, bacteremia, CMV infection and CMV disease. This has not been reported before in NMSCT patients, except for CMV infection, and could be related to poorer immune reconstitution or an increased incidence of GVHD in those patients, although GVHD per se was not associated with an increased risk in our patients. On univariate analysis, absence of DLI was associated with an increased overall risk of infection. This probably reflects the fact that DLI were mostly given in cases of transplantation with an HLA-identical sibling, but also that DLI may enhance immune recovery. For infections other than bacteremia, only the use of corticosteroids significantly increased the risk. The influence of corticosteroids on infection risk is well described in the literature. 9, 11, 12, 16, 17, 35 The initial disease category gave inconsistent information, with lymphoma patients having more CMV disease. The use of TBI or graft manipulation were not linked to an increased risk of infection in our population.
In conclusion, NMSCT recipients are at risk for the same type of infections with the same kind of pathogens as myeloablative transplant recipients. However, infections are less frequent in the first 30 days post transplant. Methods of prophylaxis, empirical antibiotic therapy and pre-emptive treatments should be the same as for conventional allografts. Careful long-term monitoring of these patients is necessary.
